Fda grants soligenix orphan drug designation for the prevention and post-exposure prophylaxis against sudan ebolavirus infection

Provides suvax™   heat stable vaccine seven years of u.s. market exclusivity upon fda approval princeton, n.j. , april 11, 2024 /prnewswire/ -- soligenix, inc. (nasdaq: sngx) (soligenix or the company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the office of orphan products development of the united states (u.s.) food and drug administration (fda) has granted orphan drug designation to the active ingredient in suvax™, the subunit protein vaccine of recombinantly expressed sudan ebolavirus (sudv) glycoprotein, for "the prevention and post-exposure prophylaxis against sudv infection.
SNGX Ratings Summary
SNGX Quant Ranking